Taipei, Taiwan In 2002 was created TaiAn Technologies, which is appeared as Corporate Investor. The main office of represented Corporate Investor is situated in the Taipei. The venture was found in Asia in Taiwan.
The top activity for fund was in 2016. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in less than 2 deals every year.
Besides, a startup requires to be at the age of 1 and less years to receive the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. The fund has exact preference in a number of founders of portfolio startups. Among the most popular fund investment industries, there are Therapeutics, Biotechnology. Among the various public portfolio startups of the fund, we may underline Sapience Therapeutics, Sapience Therapeutics
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the TaiAn Technologies, startups are often financed by Healthlink Capital, Eshelman Ventures, Celgene. The meaningful sponsors for the fund in investment in the same round are Healthlink Capital, Eshelman Ventures, Celgene. In the next rounds fund is usually obtained by Michael J. Fox Foundation, Healthlink Capital, Eshelman Ventures.
| Fund Name | Location |
| Edge Group | Houston, Texas, United States |
| Pinguan Media | China, Hubei, Wuhan |
| Remote Control Productions, Inc | - |
| RightVentures | California, San Francisco, United States |
| Ritter Starkstromtechnik | Dortmund, Germany, Nordrhein-Westfalen |
| Security Growth Partners | New York, New York, United States |
| ShangPharma Innovation | California, San Francisco, United States |
| the Etchart Group | - |
| Triad Retail Media | Florida, St. Petersburg, United States |
| Van Herk Ventures | Rotterdam, The Netherlands, Zuid-Holland |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
AnBogen Therapeutics | $12M | 31 Jan 2024 | Taiwan, Taitung County, Taiwan | ||
APRINOIA Therapeutics | $11M | 16 Jan 2018 | Taiwan, New Taipei | ||
Sapience Therapeutics | $22M | 12 Jul 2016 | New York, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
AnBogen Therapeutics | $12M | 31 Jan 2024 | Taiwan, Taitung County, Taiwan | ||
APRINOIA Therapeutics | $11M | 16 Jan 2018 | Taiwan, New Taipei | ||
Sapience Therapeutics | $22M | 12 Jul 2016 | New York, United States |
